From the Institute of Biotechnology (A.L., P.P., L.P., P.A.), University of Helsinki, Finland; Sleep-Wake Disorders Unit (L.B., Y.D.), Department of Neurology, Gui-de-Chauliac Hospital, CHU Montpellier, University of Montpellier; National Reference Network for Narcolepsy (L.B., Y.D.), CHU Montpellier; PSNREC (L.B., Y.D.), University of Montpellier, INSERM, France; and Department of Neurology (P.P., F.S.), Helsinki University Hospital and Department of Clinical Neurosciences (Neurology), University of Helsinki, Finland.
Neurol Neuroimmunol Neuroinflamm. 2020 Oct 9;7(6). doi: 10.1212/NXI.0000000000000896. Print 2020 Nov.
To test the hypothesis that narcolepsy type 1 (NT1) is related to the gut microbiota, we compared the microbiota bacterial communities of patients with NT1 and control subjects.
Thirty-five patients with NT1 (51.43% women, mean age 38.29 ± 19.98 years) and 41 controls (57.14% women, mean age 36.14 ± 12.68 years) were included. Stool samples were collected, and the fecal microbiota bacterial communities were compared between patients and controls using the well-standardized 16S rRNA gene amplicon sequencing approach. We studied alpha and beta diversity and differential abundance analysis between patients and controls, and between subgroups of patients with NT1.
We found no between-group differences for alpha diversity, but we discovered in NT1 a link with NT1 disease duration. We highlighted differences in the global bacterial community structure as assessed by beta diversity metrics even after adjustments for potential confounders as body mass index (BMI), often increased in NT1. Our results revealed differential abundance of several operational taxonomic units within Bacteroidetes, , and between patients and controls, but not after adjusting for BMI.
We provide evidence of gut microbial community structure alterations in NT1. However, further larger and longitudinal multiomics studies are required to replicate and elucidate the relationship between the gut microbiota, immunity dysregulation and NT1.
为了验证假说，即 1 型发作性睡病（NT1）与肠道微生物群有关，我们比较了 NT1 患者和对照组的微生物群细菌群落。
共纳入 35 名 NT1 患者（51.43%为女性，平均年龄 38.29±19.98 岁）和 41 名对照组（57.14%为女性，平均年龄 36.14±12.68 岁）。收集粪便样本，采用标准化的 16S rRNA 基因扩增子测序方法比较患者和对照组之间的粪便微生物群细菌群落。我们研究了患者和对照组之间、NT1 患者亚组之间的 alpha 和 beta 多样性以及差异丰度分析。
我们未发现 alpha 多样性存在组间差异，但在 NT1 中发现了与 NT1 疾病持续时间有关的差异。即使在调整了潜在混杂因素（如体重指数（BMI），NT1 中通常会增加）后，我们仍发现 beta 多样性指标评估的全球细菌群落结构存在差异。我们的结果显示，在 NT1 患者和对照组之间，Bacteroidetes、和 中的几个操作分类单元的丰度存在差异，但在调整 BMI 后则不存在差异。
我们提供了 NT1 肠道微生物群落结构改变的证据。然而，需要进一步进行更大规模和纵向的多组学研究，以复制和阐明肠道微生物群、免疫失调与 NT1 之间的关系。
